Compare RQI & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RQI | NUVB |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | United States | United States |
| Employees | N/A | 291 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | N/A | N/A |
| Metric | RQI | NUVB |
|---|---|---|
| Price | $12.65 | $4.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $11.22 |
| AVG Volume (30 Days) | 484.2K | ★ 4.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 8.20% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $182.76 |
| Revenue Next Year | N/A | $91.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.39 | $1.57 |
| 52 Week High | $13.39 | $9.75 |
| Indicator | RQI | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 44.66 | 35.60 |
| Support Level | $12.14 | $3.18 |
| Resistance Level | $13.38 | $5.73 |
| Average True Range (ATR) | 0.19 | 0.34 |
| MACD | -0.08 | -0.06 |
| Stochastic Oscillator | 22.83 | 29.62 |
COHEN & STEERS QUALITY INCOME REALTY FUND INC is a diversified, closed-end management investment company. The primary investment objective of the fund is high current income through investment in real estate securities. Its secondary objective is capital appreciation. The Fund invests at least its total assets in income-producing common stocks and other securities issued by real estate companies, such as real estate investment trusts under normal market conditions.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.